UK Public Sector Contracts & Tenders

HealthTrust Europe is establishing a Framework Agreement to appoint suppliers capable of providing a fulIrange of Outsourced Goods & Services it is intended the framework will be divided into the following lots: Lot 8 – Outsourced Dental Laboratory Services Goods and Services for this Lot encompasses the manufacture, customization of a variety of products to assist in the provision of oral health care by a licensed dentist. These products will include the production and restoration of crowns, bridges, dentures, and other dental products such as dental implants. Lot 9 – Outsourced Orthodontic Services Goods and services for this lot encompasses the goods and services of orthodontics that focuses on the correction of irregularities in the teeth (especially alignment and occlusion) and jaws. This includes treating and controlling various aspects of facial growth (dentofacial orthopaedics) and the shape and development of the jaw. Lot 10 – Dental Services This lot is a Healthcare Facility focused on diagnosing, preventing and treatment of the oral health concerns of patients. Its primary role is to provide dental care and promote good oral hygiene for patients. The Dental Service will offer a range of services designed to address different aspects of oral health, from routine check-ups and preventative care to advanced restorative and cosmetic treatment The bodies to whom the use of this framework will be open include all contracting authorities in the United Kingdom as defined in Section 1 of the Procurement Act 2023. In particular, the entities in the UK (especially those of a health and/or social care nature) listed in the downloadable spreadsheet at the following link are envisaged as framework users: https://www.ons.gov.uk/methodology/classificationsandstandards/economicstatisticsclassifications/introductiontoeconomicstatisticsclassifications This list includes each organisation’s successors and assigns, any equivalent organisations, and associated organisations created due to any organisational changes. This framework will be open to: Any bodies or organisations operating in the UK of a health and/or social care nature; Any organisations with similar procurement needs; Any UK-based central government authority listed in Annex I of Directive 2014/24/EU, to the extent still relevant under retained EU law and consistent with the Procurement Act 2023.

This framework agreement is for the supply of a range of aseptically prepared, batch manufactured systemic anti-cancer therapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific systemic anti-cancer therapy drugs, CIVAs, and provisions for stock inventory management and supply of compounded systemic anti-cancer therapy.